Tiziana Life Sciences reveals positive clinical results for MS patients treated with ForalumabProactive Investors • 10/16/23
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal ForalumabGlobeNewsWire • 10/16/23
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment dataProactive Investors • 10/16/23
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patientsProactive Investors • 10/13/23
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)GlobeNewsWire • 10/13/23
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual CongressProactive Investors • 10/11/23
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual CongressGlobeNewsWire • 10/11/23
Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMSProactive Investors • 09/26/23
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple SclerosisGlobeNewsWire • 09/26/23
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/08/23
Tiziana Life Sciences highlights publication of promising intranasal foralumab in Alzheimer's study resultsProactive Investors • 09/06/23
Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND ClearanceGlobeNewsWire • 09/06/23
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development OfficerGlobeNewsWire • 08/23/23
Tiziana Life Sciences investigational therapeutic foralumab in the spotlight at neuroimmunology eventProactive Investors • 08/23/23
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of NeuroimmunologyGlobeNewsWire • 08/23/23
Tiziana Life Sciences anticipates pivotal Phase 2 Alzheimer's trial results in fall 2024Proactive Investors • 08/17/23
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's DiseaseGlobeNewsWire • 08/17/23
Tiziana Life Sciences shares skyrocket after FDA greenlights intranasal foralumab for Alzheimer's diseaseProactive Investors • 08/15/23
Tiziana Life Sciences' stock soars 41% premarket after FDA clear path for trial of intranasal treatment for Alzheimer's diseaseMarket Watch • 08/15/23
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 08/15/23
Tiziana promotes chief medical officer Dr Matthew Davis to chief operating officerProactive Investors • 06/13/23
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating OfficerGlobeNewsWire • 06/13/23
Tiziana Life Sciences finds promising indicator of MS treatment successProactive Investors • 06/05/23
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple SclerosisGlobeNewsWire • 06/05/23